Second look laparotomy in the management of XXXX .

@entity1 @entity43 @entity5 @entity787 @entity865 @entity10224
In the present study we examined 15 @entity1 with @entity43 who underwent primary surgery and chemotherapy at the Institute of Obstetric and Gynecologic Clinic of the University of Pisa between 1983 and 1985. At the time of diagnosis and monthly during chemotherapy plasma levels of @entity787 , CA 19-9, @entity10224 and @entity865 were detected. At the end of pharmacological treatment a second-look laparotomy was performed in each @entity1 to assess the status of @entity5 . At this time the clinical response was complete in 13 @entity1 and partial in 2. These results were confirmed at second-look laparotomy in 11 of 13 cases of complete clinical remission and in 1 of the 2 cases of partial clinical remission. Two @entity1 in complete clinical remission showed persistent disease. The other one in partial clinical remission was surgically found to have unmodified @entity5 . Tumoral markers, and especially @entity10224 , have a good correlation with the clinical course of the disease. However these @entity5 associated antigens cannot replace second-look laparotomy for assessing the response to cytostatic drugs. In fact @entity1 with normal serum levels of these markers at the end of chemotherapy, were surgically found to have both complete pathological remission and persistent disease. Therefore we have come to the conclusion that the second-look laparotomy and the evaluation of @entity5 markers have to be performed together in the management of @entity43 .
